Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorit é de Santé (HAS)

Clinical study reports should be improved in terms of reporting censoring, while stakeholders should be aware of this potential source of bias. At a minimum, sensitivity analysis that ignores intercurrent events should be requested.

Source: European Journal of Cancer - April 11, 2024 Category: Cancer & Oncology Authors: Etienne Lenglin é, Joachim Baba, Paul de Boissieu, Alexandre Beaufils, Alice Desbiolles, Thierno Diatta, Pierre Cochat, Sylvie Chevret Tags: Original Research Source Type: research